“Budget impact analysis of the use of daclatasvir in Italy for the treatment of Hepatitis C Virus (HCV) genotype 3 patients”, FE, vol. 17, no. 1, pp. 7–12, Mar. 2016, doi: 10.7175/fe.v17i1.1225.